'Quiet' FDA panel rejects QRxPharma's opioids combo MoxDuo
This article was originally published in Scrip
Even though an FDA panel of advisers unanimously rejected QRxPharma's morphine/oxycodone combination drug MoxDuo as a treatment for patients with moderate-to-severe acute pain over the product's individual components or other single-entity opioids, the expert advisers gave little insight into what they were thinking.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.